Berta Hernandez

Irunlarrea St, 3, 
Pamplona, NC, ES 
Irunlarrea St, 3, 
Pamplona, NC, ES 

Overview

Berta Hernandez practices practicing medicine in Pamplona, Spain.

Her clinical expertise encompasses Lung Cancer and Non-Small Cell Lung Cancer (NSCLC).

She is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Irunlarrea St, 3, Pamplona, NC 31008, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Enrollment Status: Terminated
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
T790M Mutation Testing in Blood by Different Methodologies_RING Project
T790M Mutation Testing in Blood by Different Methodologies_RING Project
Enrollment Status: Completed
Publish Date: April 08, 2020
Intervention Type: Drug
View 2 Less Clinical Trials

10 Total Publications

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 07, 2020

Frequently Asked Questions about Berta Hernandez

Is Berta Hernandez a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Berta Hernandez is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Berta Hernandez participate in research or clinical trials?

Yes. Berta Hernandez has published 10 articles and abstracts on conditions like Lung Cancer. You can view a list of Berta Hernandez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hernandez's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile